文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 2013年中抗体药物回顾
侵权投诉

2013年中抗体药物回顾

Editor’s cornErmAbs 5:4, 513–517; July/August 2013; © 2013 Landes Bioscience

Antibodies to watch in 2013Mid-year update

Janice M. reichert

Editor-in-chief, mAbs; Landes Bioscience; Austin, tX UsA

the transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are

proceeding at a rapid pace in 2013. since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab

emtansine) received their first approvals, first marketing applications for three mAbs (vedolizumab, ramucirumab,

obinutuzumab) were submitted to regulatory agencies, and five mAbs (brodalumab, MABp1, moxetumomab pasudotox,

tildrakizumab, rilotumumab) entered their first Phase 3 studies. the current total of commercially-sponsored antibody

therapeutics undergoing evaluation in late-stage studies is 30. recently announced study results for farletuzumab,

naptumomab estafenatox, and tabalumab indicate that clinical endpoints were not met in some Phase 3 studies of these

product candidates.

Early 2013 proved to be a sufficiently busy period for anti-The parental trastuzumab was first approved in 1998 and anti-body therapeutics developers that this mid-year update to mAbs HER2 pertuzumab (PERJETA ; Genentech/Roche) was first annual coverage of antibodies in late-stage development1-4 was approved in 2012 as treatments for HER2-positive metastatic needed. A total of five antibody therapeutics (itolizumab, trastu-breast cancer. In the European Union, trastuzumab and per-zumab emtansine, vedolizumab, ramucirumab, obinutuzumab) tuzumab are approved, and trastuzumab emtansine is under-transitioned to either the market or regulatory review. Biocon going regulatory review. Trastuzumab emtansine is approved announced in January 2013 that the marketing application for patients who were previously treated with trastuzumab and for itolizumab (Alzumab) had been authorized by the Drugs taxanes. It is currently also undergoing evaluation in the Phase Controller General of India. Itolizumab is a humanized mAb that 3 MARIANNE study (NCT01120184) of trastuzumab emtan-targets CD6, which is predominantly expressed by T cells and a sine and pertuzumab vs. trastuzumab plus a taxane in patients subset of B cells. In the 52-week TREAT-PLAQ study conducted with metastatic breast cancer; the Phase 3 TH3RESA study in India, interim results indicated that patients with psoriasis area (NCT01419197) of trastuzumab emtansine compared with treat-severity index (PASI) of > 20 at baseline had PASI 75-response ment of physician’s choice in patients with HER2-positive meta-(i.e., improvement from baseline of ≥ 75%) rates of 43% and 54% static breast cancer who have received at least two prior regimens at week 12 and 28, respectively. Patients in the fixed dose treat-of HER2 directed therapy; and the Phase 3 KATHERINE study ment arm of the study received 1.6 mg/kg every two weeks for 12 (NCT01772472) of trastuzumab emtansine vs. trastuzumab as weeks followed by 1.6 mg/kg every four weeks for 16 weeks; those adjuvant therapy for patients with HER2-positive primary breast in the induction dose arm received 0.4 mg/kg every two weeks for cancer who have residual tumor present pathologically in the 12 weeks followed by 1.6 mg/kg every four weeks for 16 weeks. breast or axillary lymph nodes following preoperative therapy, Biocon is reportedly planning to launch itolizumab in India as a which was initiated in April 2013. In addition, the safety and treatment for moderate-to-severe psoriasis in the July–September efficacy of the mAb are being evaluated in an adaptive Phase 2/3 2013 quarter. The company has indicated that itolizumab has also study (NCT01641939) of patients with previously treated, locally shown promising efficacy in other autoimmune disorders, includ-advanced or metastatic HER2-positive gastric cancer, including ing rheumatoid arthritis (RA) and multiple sclerosis (MS).adenocarcinoma of the gastroesophageal junction.

n February 2013, trastuzumab emtansine (KadcylaTM; n early March 2013, Takeda Pharmaceutical Company Genentech/Roche) was approved by the US Food and Drug announced that they submitted a marketing authorization appli-Administration (FDA) as a treatment for human epidermal cation to the European Medicines Agency for vedolizumab, a gut-growth factor receptor (HER)2-positive metastatic breast cancer. selective, anti-a4b7 humanized mAb intended as a treatment for Trastuzumab emtansine is an antibody-drug conjugate (ADC) adults with moderate-to-severe active ulcerative colitis (UC) and comprising trastuzumab (Herceptin®; Genentech/Roche) linked Crohn disease (CD). The application included data from four to ImmunoGen’s DM1 maytansinoid drug. The ADC is the Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III third anti-HER2 monoclonal antibody (mAb) on the US market. and GEMINI Long-term Safety, that evaluated the efficacy and *Correspondence to: Janice M. Reichert; Email: janice.reichert@landesbioscience.com

Submitted: 05/05/13; Accepted: 05/05/13doc.guandang.net

doc.guandang.net mAbs 513©2013 Landes Bioscience. Do not distribute.

第1页

你可能喜欢

  • 药物研发
  • 抗体应用
  • 抗体工程
  • 抗体制备
  • 产业研究报告

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email